Table I.
Effect of mAbs to Leukocyte Adhesion Molecules on PMN-induced Changes in HUVEC [Ca2+]i
| Percent inhibition | ||||||||
|---|---|---|---|---|---|---|---|---|
| PMN treatment | CSLEX1 (anti-sLex) | 60.3 (anti-CD18) | M89D3 (anti–PECAM-1) | 60.3 + M89D3 | ||||
| HUVEC treatment | ||||||||
| Hist 5 min | 86.6 ± 2.1* | 16.3 ± 5.9 | 5.9 ± 3.2 | ND | ||||
| LPS 5 h | 84.5 ± 5.8* | 3.1 ± 5.2 | 3.4 ± 9.6 | 2.1 ± 3.4 | ||||
PMN were treated for 60 min in the presence or absence of mAb CSLEX1, mAb 60.3 and mAb M89D3 (20 μg/ml). HUVEC monolayers were treated for 5 min with 50 μM histamine, or for 5 h with 0.5 μg/ml E. coli LPS. PMN were then added to the monolayers (PMN/HUVEC ratio = 6–8:1) and fluorescence changes were recorded for 15 min in single Fura2-loaded HUVEC maintained in intact monolayers. Inhibitions were calculated by comparing the areas delineated by fluorescence spikes induced by mAb-treated and -untreated (control) PMN. To make recordings comparable to each other, a maximal increase in HUVEC [Ca2+]i was induced by the addition of 200 μM histamine at the end of each recording. Results are means ± SE of 3–4 independent experiments, with 10–15 replicate recordings in each experiment.
P < 0.005 (paired t test). The other results were not significantly different from control values. ND, not determined.